Effects of 2 weeks of treatment with fluticasone propionate 100 mcg b.d. by comparison with zafirlukast 20 mg b.d. on bronchial hyper-responsiveness in patients with mild to moderate asthma This study was designed to compare the eects of low-dose inhaled¯uticasone propionate (100 mcg twice daily) with those of the leukotriene antagonist, za®rlukast (20 mg twice daily), on bronchial hyper-responsiveness. The study recruited 30 patients (nine men, 21 women; mean age 45 years) with forced expiratory volume in 1 sec (FEV 1 ) >50% and airway reversibility to salbutamol !15%. This was a single centre, double-blind, double-dummy crossover study, composed of two successive 2-week treatment periods, each preceded by a 2±4 week single-blind placebo period. Following 2 weeks of treatment with¯uticasone propionate and za®rlukast, the mean provocational concentration causing a 20% fall in FEV 1 (PC 20 ) histamine was 1?61 mg ml 71 (SD 2?34) and 0?99 mg ml 71 (SD 1?74) respectively. Taking baseline dierences into account, the dierence between treatments was equivalent to 0?77 doubling doses of histamine (95% CI, 0?05±1?50; P=0?037). Morning peak¯ow values were signi®cantly higher (17 l min 71 ; P=0?049) after treatment with¯uticasone propionate during the second week of treatment. Both treatments were well tolerated. The results of this short-term study show that compared with za®rlukast, a low dose of¯uticasone propionate oers greater clinical bene®t and is more cost eective.
Introduction
Fluticasone propionate, an inhaled corticosteroid established in the treatment of asthma, has been shown to bene®t from an improved ecacy to safety ratio when compared with other inhaled steroids. Studies in both adults and children assessing lung function, symptoms and extra bronchodilator usage have shown that¯uticasone propionate is more eective than beclomethasone dipropionate (1±3) or budesonide (1, 4, 5) when used at half the dose of these inhaled corticosteroids. When used in chronic treatment,¯uticasone propionate at doses of 750 mcg day 71 and above have been shown to be very eective in decreasing bronchial hyper-responsiveness (6±8). Its ecacy in this respect was achieved at half the dose of beclomethasone dipropionate (8) .
Although many mediators are involved in the pathogenesis of asthma, there is evidence to suggest that cysteinyl leukotrienes are important mediators of the asthmatic response (9) . A number of studies have demonstrated that leukotrienes are potent bronchoconstrictors (10) as well as inducers of mucus hypersecretion (11) and airway oedema (12) . It has been shown that the urinary leukotriene E 4 (LTE 4 ), used as a marker for whole body cysteinyl leukotriene production, increases following allergen challenge (13) and during acute asthma attacks (14) . However, no correlation has been found between the severity of clinical asthma and the level of LTE 4 in the urine of stable asthmatic patients (15) .
Several placebo-controlled studies have demonstrated that chronic treatment with leukotriene antagonists results in decreased asthmatic symptoms, improved lung function and decreased use of bronchodilator (16±19) with measurable eects being achieved within 3±14 days of therapy (19) . Leukotriene receptor antagonists, as well as drugs which interfere with leukotriene formation, have been shown to attenuate the obstructive response induced by cold, dry air hyperventilation, exercise, allergen and aspirin (20±22).
There is also some suggestion that these agents can reduce the bronchial hyper-responsiveness provoked by pharmacological stimuli (23±25). It has been proposed, therefore, that leukotriene antagonists may constitute alternative ®rstline preventative therapy for patients with mild to moderate asthma who are receiving intermittent inhaled 2 -agonist therapy (26) . However, there are very few comparative data to support this proposal.
Asthma is characterized by reversible airways obstruction, oedema and in¯ammation as well as hyper-responsiveness to provocative stimuli. Non-speci®c bronchoconstrictor stimuli such as histamine and methacholine are widely used to demonstrate bronchial hyper-responsiveness. The provocative concentration (PC 20 histamine) producing a 20% fall in forced expiratory volume in 1 sec (FEV 1 ) is used as a measure of sensitivity. This is lowered in asthmatics (27) . This study was designed to compare the eects on bronchial hyper-responsiveness of 2 weeks' treatment with low-dose¯uticasone propionate (100 mcg twice daily) and the leukotriene antagonist, za®rlukast (20 mg twice daily) respectively. Bronchial hyper-responsiveness was assessed by histamine provocation.
Methods

SUBJECTS
Non-smoking, adult patients aged 18±70 years with a documented clinical history of reversible airways disease were recruited into the study. None of the patients had used oral or inhaled coricosteroids, sodium cromoglycate, nedocromil or long-acting b 2 -agonists for at least 4 weeks before the start of the study. Other entry criteria, established during the run-in period, included: FEV 1 of at least 50% of predicted normal value; reversibility of airway obstruction of at least 15% following 200 mcg salbutamol from a metered dose inhaler (MDI) or 400 mcg salbutamol from a Diskhaler inhaler; and PC 20 histamine 4 mg ml 71 Patients were excluded from the study if they had been admitted to hospital with asthma or had received antibiotics for an upper or lower respiratory tract infection within the previous month. Other exclusion criteria included: ketotifen therapy within the previous 3 months; lactation, pregnancy or inadequate contraceptive precautions in women of child-bearing potential; inadequate inhaler and peak¯ow meter techniques. Approval was obtained from the local research ethics committee and all patients provided their written informed consent.
STUDY DESIGN
This was a randomized, double dummy, cross-over study; patients were recruited from two hospital centres. Initially, patients entered a 2±4 week, single-blind, placebo run-in period. During this period all asthma medication (apart from regular methylxanthines and anticholinergics) was replaced by inhaled salbutamol from a Diskhaler inhaler or MDI, which was to be used as necessary to relieve symptoms. Therapy for all other medical conditions was to remain constant throughout the study. Patients who ful®lled the eligibility criteria were then randomly assigned to 2 weeks' double-blind treatment (treatment period 1) with either inhaled¯uticasone propionate 100 mcg twice a day (b.d.) administered by Diskhaler inhaler or oral za®rlukast 20 mg b.d. Thereafter, patients entered a 2±4 week single-blind, wash-out period on placebo followed by a subsequent 2-week period where, again under doubleblind conditions, they received the alternative active treatment (treatment period 2). Patients were instructed to use their medication in the morning (around 0800 h) and in the evening (around 2000 h).
Assessments were performed in the clinic at the beginning and end of the placebo run-in period, at the end of treatment period 1, after the placebo washout period and at the end of treatment period 2.
At the ®rst clinic visit, demographic details and a full clinical history were recorded and a physical examination was performed. Investigators also con®rmed that patients could use an inhaler and a peak¯ow meter correctly. In addition, FEV 1 was measured using a spirometer and the highest of three values was recorded. At the beginning or end of the run-in period, airway reversibility was determined by recording FEV 1 before and 15 min after the inhalation of 200 mcg salbutamol from a MDI or 400 mcg salbutamol via Diskhaler inhaler. Histamine challenge tests were also performed at the end of the run-in period, at the end of treatment period 1 and at the end of treatment period 2 on separate days to the pulmonary function tests, but within 3 successive days. All pulmonary function and airway challenge tests were performed at 0900 h (1 h), patients were therefore requested not to use their bronchodilators for at least 4 h before each clinic visit.
Baseline lung function was recorded as the best of three reproducible values of FEV 1 (within 5%) before the provocation tests. The histamine provocation test was performed according to the method of Cockcroft et al. (28) . Aerosols of histamine were generated by a jet nebuliser with a ®xed output of 0?13 ml min 71 . A nose clip was worn and the aerosol was inhaled by tidal breathing for 30 sec. The ®rst aerosol was saline and was followed at 5-min intervals by doubling concentrations of histamine (0?125±32 mg ml). FEV 1 was measured before and 1 min after each inhalation until the reading had fallen by 20% or more from the lowest post-saline value. The results were expressed as PC 20 histamine. The exact value for PC 20 histamine was determined in mg ml 71 by linear interpolation of the last two points of the concentration±response curve All patients kept daily record cards throughout the study, recording morning and evening peak expiratorȳ ow (PEF), study medication, use of relief medication and symptoms by day and by night. Symptoms related to daily activities were rated as follows: 0 = none; 1 = symptoms for one short period; 2 = symptoms for two or more short periods; 3 = symptoms for most of the day which did not aect your normal daily activities; 4 = symptoms for most of the day which did aect your normal daily activities; 5 = symptoms so severe that you could not perform normal daily activities. Symptoms during the night related to sleep disturbance and were rated as follows: 0 = none; 1 = symptoms caused you to wake once or wake early; 2 = symptoms caused you to wake twice or more (including waking early); 3 = symptoms caused you to be awake for most of the night; 4 = symptoms so severe that you did not sleep at all. Patients were also requested to record the number of times salbutamol was required for symptomatic relief both during the day and at night.
At the beginning and end of the treatment period, blood samples were taken for routine haematology and biochemistry. In addition, the oropharynx was examined at each clinic visit and a swab was taken if clinically indicated to determine the presence of Candida spp.
STATISTICAL ANALYSIS
The level of signi®cance for all analyses was 5%, all tests were two-sided and all were based on the intention-to-treat sample. Predicted lung function values were calculated from sex, age and height using standard formulae (29) .
The primary measure of ecacy was PC 20 histamine values. Only patients who provided data for both treatment periods were included in the statistical analysis. The presence of carry-over eects was investigated using Wilcoxon's rank-sum test. Log-transformed PC 20 values were analysed by analysis of covariance (ANCOVA) adjusting for study period, patient and pre-treatment value (obtained at the start of each treatment period) as covariates and treatment as main eect.
The daily morning/evening PEF values were averaged over patients and plotted by treatment group. Baseline PEF was established by taking the mean of the last 7 days of the run-in period for each patient. Average weekly values (for week 1 and week 2) were analysed using ANCOVA as described for PC 20 histamine values and the presence of carry-over eects was investigated using Wilcoxon's ranksum test. No formal analysis was applied to symptom score data and the use of rescue bronchodilator medication.
It was estimated that 30 evaluable patients would provide 90% power to detect a treatment dierence of at least 0?7 doubling doses of histamine with a 5% level of signi®cance. This assumed a within-patient standard deviation of up to 0?75 of a doubling dose.
Results
Of the 30 patients who completed the placebo run-in period, the majority were women. Seventy-seven percent were atopic (diagnosed by skin test) and 80% had been suering from asthma for over 6 years. There were no signi®cant dierences in baseline characteristics between the two treatment sequence groups ( Table 1 ). The mean PC 20 values prior to treatment were similar in both groups (0?57 mg ml 71 for¯uticasone propionate; 0?58 mg ml 71 for za®rlukast). Only one patient was receiving concurrent anticholinergic therapy and none were receiving methylxanthines. Three patients were withdrawn from the study, two because of adverse events and one because incorrect medication was taken during the wash-out period. The remaining 27 patients completed the study.
BRONCHIAL HYPER-RESPONSIVENESS
Baseline FEV 1 values taken before histamine challenges did not dier signi®cantly between active treatment groups. Pre-saline FEV 1 values before treatment were 2?52 0?7 l and 2?0 0?69 l, for the¯uticasone propionate (n=29) and za®rlukast (n=30) groups, respectively, and post-saline values were 2?55 0?9l and 2?49 0?67 l.
There was no evidence of carry-over with respect to PC 20 (P=0?289) and all data were therefore combined. At the start of treatment PC 20 values were similar for both treatment groups. (Table 1, Fig. 1 ). The change in reactivity, however, after 2 weeks' treatment with each agent, was signi®cantly dierent: the mean PC 20 histamine was 1.61 mg ml 71 (SD 2?34) after treatment with¯uticasone propionate, compared with 0?99 mg ml 71 (SD 1?74) after treatment with za®rlukast ( Fig. 1 ). Using ANCOVA where period, patient and baseline were used as covariants, this dierence was equivalent to 0?77 doubling doses of histamine (95% CI, 0?05±1?50; P=0?037).
DAILY RECORD CARD DATA
Mean morning and evening PEF values tended to be higher in the¯uticasone propionate group than in the za®rlukast group both during the ®rst and second week of treatment. Mean morning peak¯ow is shown in Fig. 2 . A signi®cant treatment dierence (17?7 l min 71 ; P=0?049) was observed in morning PEF values during the second week ( Table 2) .
The majority of patients had no symptoms or suered from very mild symptoms throughout the study. They used very little extra relief bronchodilator and no obvious dierences were detected between the two treatments.
ADVERSE EVENTS
No serious adverse events were reported during the study. Overall, nine patients reported 14 adverse events; six patients reported 10 adverse events during treatment with uticasone propionate and three patients reported four adverse events during treatment with za®rlukast. Only one event (asthma attack during za®rlukast therapy) was judged to be related to study medication. During treatment with uticasone propionate, there were three reports of headache, two of common cold and one report each of back pain, diabetes, dizziness, ear infection and fatigue. Further investigation into the report of`diabetes' revealed that this patient had elevated blood glucose levels prior to the study. This event therefore, bears no relation to study treatment.
During treatment with za®rlukast, there was one report each of headache, asthmatic attack, fever and pyrosis. Two patients were withdrawn from the study during wash-out periods, one following¯uticasone propionate treatment (dyspnoea), the other following za®rlukast treatment (dyspnoea plus chest pains).
Liver function was assessed by monitoring levels of aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT) and gamma glutamyltransferase (GGT). No trends were apparent from the summary data and none of the changes recorded was judged to be clinically signi®cant. Apart from one patient who had an abnormal oropharyngeal throat examination at one visit, all throat examinations from all patients were normal. The physician did not, however, recommend further investigation.
Discussion
The results of this study showed that, after 2 weeks' therapy, inhaled¯uticasone propionate 100 mcg b.d. decreased bronchial hyper-responsiveness to a signi®cantly greater extent than oral za®rlukast 20 mg b.d. Lung function also tended to improve more with¯uticasone propionate than with za®rlukast. There was a clinically signi®cant dierence between treatments (17?7 l min 71 ) in morning PEF during the second week of therapy, being higher after treatment with¯uticasone propionate.
The extent to which¯uticasone propionate 100 mcg b.d. reduced bronchial hyper-responsiveness in this study is consistent with the results of a previous study involving mild asthmatic subjects during which¯uticasone propionate 1000 mcg daily for 2 weeks improved PC 20 histamine by 1?3 doubling doses (6) . The only study to have reported the eects of chronic treatment with za®rlukast on bronchial hyper-responsiveness showed that by comparison with placebo, za®rlukast 20 mg b.d. for 2 weeks was associated with a signi®cant mean shift in log PC 20 methacholine of 0?38 log dose units and that PC 20 methacholine was on average 2?5 times higher during active treatment than during placebo treatment (23) .
Two other studies have examined bronchial hyperresponsiveness after a period of treatment with a leukotriene antagonist. The ®rst was a double-blind, cross-over study which observed the eects of oral pranlukast 225 mg b.d. in the treatment of 11 stable asthmatics (24) . After 1 week of treatment, pranlukast produced a small but signi®cant improvement in bronchial hyper-responsiveness (half of one doubling dose of methacholine). The second study, in 11 subjects, found pranlukast 450 mg b.d. to be associated with improved clinical symptoms as well as improved histamine reactivity to bronchial challenge performed 12 and 24 weeks post-treatment (25) . It has been suggested that the eect of za®rlukast on bronchial hyper-responsiveness may vary depending on the duration of the medication, short-term or single dose studies failing to re¯ect the ultimate capability of antileukotriene medication. That being the case, the acute bene®ts of these drugs could not be assessed from bronchial provocation using methacholine or histamine. The same argument would apply in the case of inhaled corticosteroids, the degree of response being dependant on the severity of disease, the dose, the duration of treatment and steroid responsiveness of the patient. Indeed, it may be 12 months before inhaled steroids exert their maximum eect on bronchial reactivity (30) .
While the pathogenesis of airway hyper-responsiveness is unclear, in asthma it is linked with in¯ammation (31). In stable asthmatic patients, airway responsiveness is related to the numbers of eosinophils and mast cells which are present in bronchoalveolar lavage¯uid (BAL), the extent of mucosal in¯ammation and peripheral blood eosinophilia (31) . Eosinophils are one of the predominant in¯ammatory cells in the asthmatic lung and they play a central role in asthma (32) . A correlation has been observed between activated eosinophils and pulmonary function or non-speci®c bronchial hyper-responsiveness (33±35). The documented eect of¯uticasone propionate and za®rlukast on eosinophils is therefore worthy of mention. In a placebocontrolled, cross-over study involving 16 asthmatic patients,¯uticasone propionate 500 mcg day 71 taken over a 6-week period, signi®cantly improved methacholine provoked bronchial hyper-responsiveness and signi®cantly reduced both BAL eosinophil count and peripheral blood eosinophil count (36) . By comparison in another study, za®rlukast 20 mg b.d. has been shown to reduce the numbers of some of the in¯ammatory cells (basophils, P50?01 and lymphocytes, P50?01) in BAL¯uid following segmental allergen challenge 5 days post-treatment, but to have no eect on number of eosinophils and macrophages (37) . Pranlukast, however, has been observed to decrease BAL macrophages, neutrophils and epithelial cells (38) . The comparative eects of inhaled corticosteroids and leukotriene antagonists may account for their diering capacity to reduce bronchial hyper-responsiveness. The treatment of asthma focuses on diminishing the in¯ammatory process and bronchial hyper-responsiveness. Corticosteroids are by far the most eective and most commonly used anti-in¯ammatory agents available (39) . Leukotrienes are just one of the many groups of mediators involved in the complex in¯ammatory process leading to the clinical manifestations of asthma. In this study we found, even at a low dose and for a short treatment period, that the eects of¯uticasone propionate could be clearly dierentiated from those of za®rlukast in mild asthma. This present study suggests that the extent to which inhibiting one set of in¯ammatory mediators can be expected to attenuate the asthmatic response can be questioned. In these patients,¯uticasone propionate oers greater clinical bene®t than za®rlukast.
